title: Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.
abstract: Antibody-drug conjugates (ADC) represent a promising therapeutic modality for managing cancer. Here, we report a novel humanized ADC that targets the tetraspanin-like protein TM4SF1. TM4SF1 is highly expressed on the plasma membranes of many human cancer cells and also on the endothelial cells lining tumor blood vessels. TM4SF1 is internalized upon interaction with antibodies. We hypothesized that an ADC against TM4SF1 would inhibit cancer growth directly by killing cancer cells and indirectly by attacking the tumor vasculature. We generated a humanized anti-human TM4SF1 monoclonal antibody, v1.10, and armed it with an auristatin cytotoxic agent LP2 (chemical name mc-3377). v1.10-LP2 selectively killed cultured human tumor cell lines and human endothelial cells that express TM4SF1. Acting as a single agent, v1.10-LP2 induced complete regression of several TM4SF1-expressing tumor xenografts in nude mice, including non-small cell lung cancer and pancreas, prostate, and colon cancers. As v1.10 did not react with mouse TM4SF1, it could not target the mouse tumor vasculature. Therefore, we generated a surrogate anti-mouse TM4SF1 antibody, 2A7A, and conjugated it to LP2. At 3 mpk, 2A7A-LP2 regressed several tumor xenografts without noticeable toxicity. Combination therapy with v1.10-LP2 and 2A7A-LP2 together was more effective than either ADC alone. These data provide proof-of-concept that TM4SF1-targeting ADCs have potential as anticancer agents with dual action against tumor cells and the tumor vasculature. Such agents could offer exceptional therapeutic value and warrant further investigation. Mol Cancer Ther; 14(8); 1868-76. ©2015 AACR.
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Alberto
authors.initials: A
authors.lastname: Visintin
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Kelly
authors.initials: K
authors.lastname: Knowlton
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Edyta
authors.initials: E
authors.lastname: Tyminski
authors.affiliation: The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
authors.forename: Chi-Iou
authors.initials: CI
authors.lastname: Lin
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Xiang
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Marquette
authors.affiliation: Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
authors.forename: Sadhana
authors.initials: S
authors.lastname: Jain
authors.affiliation: Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
authors.forename: Lioudmila
authors.initials: L
authors.lastname: Tchistiakova
authors.affiliation: The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
authors.forename: Dan
authors.initials: D
authors.lastname: Li
authors.affiliation: Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: O'Donnell
authors.affiliation: Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
authors.forename: Andreas
authors.initials: A
authors.lastname: Maderna
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
authors.forename: Xianjun
authors.initials: X
authors.lastname: Cao
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
authors.forename: Robert
authors.initials: R
authors.lastname: Dunn
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
authors.forename: William B
authors.initials: WB
authors.lastname: Snyder
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Anson K
authors.initials: AK
authors.lastname: Abraham
authors.affiliation: Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism (PDM), Pearl River, New York.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Leal
authors.affiliation: Pfizer Inc., Drug Safety R&D, Investigative Toxicology, Groton, Connecticut.
authors.forename: Shoba
authors.initials: S
authors.lastname: Shetty
authors.affiliation: Pfizer Inc., Biotherapeutics Pharmaceutical Sciences, Andover, Massachusetts.
authors.forename: Anthony
authors.initials: A
authors.lastname: Barry
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Leigh
authors.initials: L
authors.lastname: Zawel
authors.affiliation: Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Coyle
authors.affiliation: The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts. sjaminet@bidmc.harvard.edu hdvorak@bidmc.harvard.edu.
authors.forename: Harold F
authors.initials: HF
authors.lastname: Dvorak
authors.affiliation: The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts. sjaminet@bidmc.harvard.edu hdvorak@bidmc.harvard.edu.
authors.forename: Shou-Ching
authors.initials: SC
authors.lastname: Jaminet
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic; D011817:Rabbits; D014018:Tissue Distribution; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; C074075:TM4SF1 protein, human